Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye [clinicaltrials:NCT02101281]

Bio2RDF uri

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye [clinicaltrials:NCT02101281]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02101281

Bio2RDF identifier

NCT02101281

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02101281

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of the stud ...... ops to patients with Dry Eye.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:24f5ce4e79432bbeb4193364f9f00427]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:3f09f3718fe461302ffa89c73326a9d4]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:48d0ade88174003cfc018294afe5c77e]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:a3552f572e98e2ff1c527c988fec4eef]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:2291a04c2ae4f3c0892f23ee160f7fa2]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:3d1113e771316502fc35ac975e9ac1f0]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:5a204b352f752248c1c1a38a6195ebc2]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:625255e8e6bc80d6506791b14f8489f3]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:66c376b6da10fe07ae7e538851b1acc5]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:6dffbddb68eb443d25e1b3fb8eee8966]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:73e13c33d2407a9104ca8777f176d620]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:8f41fc201d9738016ce5209fa061ce04]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:a39754d30b5879961a1be3e2000e168c]

Symptom Assessment in Dry Eye (SANDE) Changes from baseline up to day 56±4 [clinicaltrials_resource:d347c453d81ed85b354dcac96349ffd2]

collaborator [clinicaltrials_vocabulary:collaborator]

Dompé Farmaceutici S.p.A [clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7]

completion date [clinicaltrials_vocabulary:completion-date]

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Dry Eye Syndrome. [clinicaltrials_resource:99bd975e8c127b773955d67aaf84a496]

condition browse [clinicaltrials_vocabulary:condition-browse]

Keratoconjunctivitis Sicca [clinicaltrials_resource:9059afecb526cc957a19f6265090f8cf]

Dry Eye Syndromes [clinicaltrials_resource:b2508f22b900a2b49856cd5b32a71e95]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Keratoconjunctivitis Sicca [clinicaltrials_resource:9059afecb526cc957a19f6265090f8cf]

Dry Eye Syndromes [clinicaltrials_resource:b2508f22b900a2b49856cd5b32a71e95]

country [clinicaltrials_vocabulary:country]

Austria [clinicaltrials_resource:9891739094756d2605946c867b32ad28]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02101281 [clinicaltrials_resource:3452a6af05ae28f04e075fb4b9a4afe6]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Human nerve growth factor 4 µg/mL or 60 µg/mL [clinicaltrials_resource:10d98fdff9131c07169d36d78c834a5c]

Human nerve growth factor 20 µg/mL [clinicaltrials_resource:1a154965c65225f7c715363906ec8276]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Mitogens [clinicaltrials_resource:2a529d3c4b469dec760d382bb10e5482]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Dry Eye

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Dompé Farmaceutici S.p.A [clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7]

location [clinicaltrials_vocabulary:location]

Department of Clinical Pharmacology [clinicaltrials_resource:f19032236e540ac3fd96134ba65265b4]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02101281

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

An Open-label Study Evaluating ...... Doses in Patients With Dry Eye

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

NGF0213

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Gerhard Garhöfer, MD [clinicaltrials_resource:c06d31cd2a7bcedd44c1f2cd0be815b1]

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Austria: Agency for Health and Food Safety [clinicaltrials_resource:f3666e7fc2ddaf79ef179f912297fd93]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

2013-004271-12

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Dompé Farmaceutici S.p.A [clinicaltrials_resource:a12e3eabcf3f30732b467dd7fc0ed7a7]

start date [clinicaltrials_vocabulary:start-date]

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02101281 study design [clinicaltrials_resource:4c60eb7c35bcb1dcee2ee38b88fee5be]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02101281

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02101281

http://www.w3.org/2001/XMLSchema#string

title

Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Safety and Efficacy of rhNGF E ...... e [clinicaltrials:NCT02101281]

@en